Ignite Creation Date:
2024-07-17 @ 11:00 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06471959
Status:
RECRUITING
Last Update Posted:
2024-06-24
First Post:
2023-12-11
Brief Title:
Psychedelic-assisted Group Program for First Responders
Sponsor:
Empower Research Inc
Organization:
Empower Research Inc
Study Overview
Official Title:
Assessing the Feasibility of a Custom Psychedelic-assisted Group Program on Mental and Physical Health in First Responders
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a two-group feasibility study of oral psilocybin combined with a 12-week group-based program customized for firefighters Trained facilitators will help create a trauma-informed space for the group n 6-8 to thrive and promote cognitive resilience The topics covered throughout the 12 weeks include breath-work mindfulness self-compassion embodiment and Internal Family Systems work
Group 1 control 12-week group-based program with a breathwork day at week 10
Group 2 intervention 12-week group-based program with a 10mg dose of psilocybin PEX010 at Week 10
Assessment timepoints
Baseline
Mid-program Week 6
End of program Week 12
6-month follow up
Group 1 control 12-week group-based program with a breathwork day at week 10
Group 2 intervention 12-week group-based program with a 10mg dose of psilocybin PEX010 at Week 10
Assessment timepoints
Baseline
Mid-program Week 6
End of program Week 12
6-month follow up
Detailed Description:
All participants will undergo a 12-week group-based program one session per week for 12 weeks The first group session as well as the Week 10 session will occur in-person The remainder of the sessions will occur remotely Each week trained facilitators will help create a trauma-informed safe space for the group to thrive and promote cognitive resilience The topics covered throughout the 12-week program include breath-work mindfulness self-compassion embodiment and Internal Family Systems work
During Week 10 participants will be provided with either psilocybin active group or complete a breathwork day control group For participants randomized to the active group they will receive 10mg of psilocybin on Week 10 A clinician certified and trained in the therapeutic use of psilocybin will be on site for participants in the psilocybin group During the dosing session the clinicians will respond to whatever needs arise This may include escorting them to the bathroom giving them a drink of water At least two staff one facilitator and one clinician will be on site during dosing days
The dose will be administered in clear capsules with approximately 500ml of water Aside from the dose provided the weekly session will continue as usual with a focus on breath-work embodiment and gentle movement on dosing days
Psilocybin in the study comes in the form of the study drug PYEX PYEX is a drug substance which is a partially purified fraction of the extract of Psilocybe cubensis mushroom fruiting bodies It is a mixture of indole alkaloids other mushroom fruiting body components and stabilization excipients The major indole alkaloids present include psilocybin and psilocin dephosphorylated psilocybin PEX010 is a capsule for oral administration and is manufactured with PYEX 125-140 psilocybin excipients and HPMC hydroxypropyl methyl cellulose capsules
During Week 10 participants will be provided with either psilocybin active group or complete a breathwork day control group For participants randomized to the active group they will receive 10mg of psilocybin on Week 10 A clinician certified and trained in the therapeutic use of psilocybin will be on site for participants in the psilocybin group During the dosing session the clinicians will respond to whatever needs arise This may include escorting them to the bathroom giving them a drink of water At least two staff one facilitator and one clinician will be on site during dosing days
The dose will be administered in clear capsules with approximately 500ml of water Aside from the dose provided the weekly session will continue as usual with a focus on breath-work embodiment and gentle movement on dosing days
Psilocybin in the study comes in the form of the study drug PYEX PYEX is a drug substance which is a partially purified fraction of the extract of Psilocybe cubensis mushroom fruiting bodies It is a mixture of indole alkaloids other mushroom fruiting body components and stabilization excipients The major indole alkaloids present include psilocybin and psilocin dephosphorylated psilocybin PEX010 is a capsule for oral administration and is manufactured with PYEX 125-140 psilocybin excipients and HPMC hydroxypropyl methyl cellulose capsules
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None